

CURRICULUM VITAE
Reham Abdelwahab Hassan Ali, MD, PhD



PRESENT TITLE AND AFFILIATION

Primary Appointment

- Lecturer and consultant, Department of Clinical Oncology, Faculty of Medicine, Assiut University Hospitals, Assiut University, Egypt

CITIZENSHIP

Arab Republic of Egypt

Nationality

Egyptian

Date of Birth

December 5th, 1981

OFFICE ADDRESS

Clinical Oncology Department, Assiut University Hospitals
Assiut Faculty of Medicine, Assiut University
Assiut, Egypt
Phone: +201017324117
Phone: +20882054232
Email: rabdelwahab@aun.edu.eg

EDUCATION

Degree-Granting Education

- Bachelor of Medicine and Surgery Degree (MD), Assiut University, Faculty of Medicine, Assiut, Egypt, 2005
- Master of Science Degree in Clinical Oncology, Assiut University, Faculty of Medicine, Assiut, Egypt, 2009
- Doctor of Science Degree in Clinical Oncology, Assiut University, Faculty of Medicine, Assiut, Egypt, 2015

Postgraduate Training

Clinical

- Clinical Internship, Assiut University Hospitals, Assiut, Egypt, 3/2005-2/2006
 - ❖ Training goal included 2 months clinical training in Departments of Gynecology & Obstetrics, General Surgery, Pediatrics, Internal Medicine, Anesthesia, and Emergency Unite.
- Clinical Residency, Department of Clinical Oncology, Assiut University Hospitals, Assiut, Egypt, 3/2006-2/2008
- Chief Clinical Resident, Department of Clinical Oncology, Assiut University Hospitals, Assiut, Egypt, 3/2008-2/2010
 - ❖ Clinical training included how to diagnose and manage adults and children with malignancy, how to manage oncologic emergency, and how to use the traditional radiotherapy techniques. The training focused on attending daily ward rounds, daily outpatient clinic, three times weekly night shifts at night and in the weekends, providing medical service under direct supervision of the fellows and consultants, supervising the house officers and medical students, and learning different clinical procedures. The training also included attending clinical rounds and seminars, and presenting cases in the department scientific meetings, and in the Hospital Grand Rounds.
- Visiting Clinical Fellowship, Department of Radiation Oncology, Children's Cancer Hospital Egypt (CCHE)-57357, Cairo University, Cairo, Egypt, 5/2009-7/2009
 - ❖ Clinical Training focused on attending the clinics, treatment planning including CT simulators, radiotherapy network flow work, target delineation with MRI and PET-CT fusion, 3-dimensional conformal treatment planning (3DCRth), intensity modulated radiotherapy (IMRT) and image guided radiotherapy (IGDT). I

attended the weekly scientific meeting and shared in all departmental scientific activities.

- Clinical Fellowship, Department of Clinical Oncology, Assiut University Hospitals, Assiut, Egypt, 3/2010-2/2013
- Senior Clinical Research Fellowship, Department of Clinical Oncology, Assiut University Hospitals, Assiut, Egypt, 3/2013-11/2015
 - ❖ Clinical training included how to diagnose and manage adults and children with malignancy, how to manage oncologic emergencies, and how to use the new radiotherapy techniques. The training focused on attending daily ward rounds, daily outpatient clinic, providing a 24 hour medical service within the hospital in conjunction with the residents and house officers, follow the instructions and written protocols of the consultants for each individual case and inform the consultants of any change in the patients' medical condition, initiate prescriptions to inpatients and document their progress in clinical notes, perform different clinical procedures, and carry out emergency procedures. The training also included presenting cases in the weekly scientific meetings of the department, and Hospital Grand Rounds, and share with various scientific activities in the Annual Faculty Conference, and the Annual Assiut Clinical Oncology Department Conference.
- Clinical Observership, Department of Radiation Oncology, Ontario Research Institute, University Health Network, University of Toronto, Toronto, Canada, 7/2011
 - ❖ Clinical training goals focused on attending the clinics, treatment planning including intensity modulated radiotherapy (IMRT) and image guided radiotherapy. Also, attending the multidisciplinary tumor boards with lung, central nervous system, genitourinary, and gynecological tumors.
- Clinical Observership, Department of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Canada, 10/2011-11/2011
 - ❖ Clinical training goals focused on attending the hematology/oncology ward rounds, outpatients' clinics, bedside teaching, and postgraduate lectures.
- Visiting Clinical Resident, Division of Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark, 9/2012
 - ❖ This was a Technology Transfer Grant from European Society for Radiation and Oncology (ESTRO) to learn the new technique of image guided brachytherapy for gynecological cancers. I also attended the oncology ward rounds, outpatient clinics, bedside teaching, and postgraduate lectures.

Research

- Post-Graduate Student, Faculty of Medicine, Assiut University, Assiut, Egypt, 10/2006-12/2009
 - ❖ **Mentors: Prof. Mohammed Mekkawy, MD, PhD**
Prof. Samir Shehata, MD, PhD
Prof. Hanan Mostafa, MD, PhD
 - ❖ Thesis entitled "Role of Stereotactic Radiotherapy in Management of Deeply Seated Tumors"
http://srv4.eulc.edu.eg/eulc_v5/Libraries/Thesis/BrowseThesisPages.aspx?fn=PublicDrawThesis&BibID=10501780,2008,P1-127
- Visiting Scientist, Department of Medical Biophysics, Princess Margaret Hospital, University of Toronto, Toronto, Canada, 5/2011-6/2011
- Visiting Scientist, Department of Medical Biophysics, Ontario Research Institute, University Health Network, University of Toronto, Toronto, Canada, 8/2011-9/2011
 - ❖ **Mentor: Lothar Lilge**
 - ❖ Research training goals focused on
 - ✚ Learning and practice the procedures associated with out optical breast cancer risk assessment program (called TIBS). The objectives of the long-term program are to develop a prescreening program for women as young as in their twenties to identify those at a higher risk for breast cancer than the average population, enabling a more personalized screening program for the entire population
 - ✚ Development of Photodynamic Therapy (PDT) for oncological and infectious disease applications. I trained on the process of microorganism sterilization, tissue culture steps, colorimetric survival assays, some animal surgical skills, and in vitro and in vivo assessment of the efficacy of novel photosensitizers

in mammalian cell lines.

- Post-Graduate Student, Faculty of Medicine, Assiut University, Assiut, Egypt, 4/2010-10/2015
 - ❖ Thesis entitled “Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma” Manuscript published in *Oncotarget*.
 - ✚ **Mentors:**
 - **Prof. Samir Shehata, Department of Clinical Oncology, Faculty of Medicine, Assiut University**
 - **Prof. Hoda Hassan, Department of Clinical Oncology, Faculty of Medicine, Assiut University**
 - **Dr. Ahmed Kaseb, MD, Department of GI Medical Oncology, MD Anderson Cancer Center**
 - ✚ The study results supported the initiation of an international collaborative project between the HCC team at UT-MDACC, and Yonsei University College of Medicine in South Korea, Sun Yat-sen University Cancer Center in China, Mahidol University in Thailand, Hacettepe University in Turkey, and three Egyptian Universities including Assiut University, Mansoura University, and Cairo University aiming to initiate the Hepatocellular Carcinoma International Biomarkers Assessment Consortium (HIBAC). Dr. Kaseb is the leader of this consortium that was funded from the MD Anderson Cancer Center Global Academic Program (GAP) and I was coordinating the scientific work of all institutions, recruiting blood samples from MD Anderson’s HCC patients, and train our Egyptian collaborators to recruit patients and collect blood samples.
 - ❖ Other research projects:
 - ✚ Developed the protocol for a phase III trial of administration of paclitaxel and cisplatin concurrently with radiotherapy in muscle invasive bladder cancer compared to cisplatin alone. Manuscript published in *Annals of Cancer Research*.
 - ✚ Participated in developing the protocol to investigate the role of concurrent chemoradiotherapy with weekly Docetaxel and Cisplatin in treating locally advanced head and neck cancers. Manuscript published in *Cancer Biology*.
 - ✚ Collaborated in writing a case report about giant recta villous adenoma. Manuscript published in *Gastrointestinal Cancer Res.*
- Postdoctoral Fellowship, Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA, 9/2013-9/2018
 - ❖ Postdoctoral fellow, Hepatocellular Carcinoma group, 2013-2017
 - ✚ **Mentors: Dr. Manal Hassan, MD, MPH**
Dr. Ahmed Kaseb, MD
 - Examined the impact of incorporating IGF-1 into different hepatocellular carcinoma prognostic and staging systems.
 - Participated in retrospective review of 3000 HCC patients as a part of epidemiological case-control study to analyze various debatable risk factors for Hepatocellular Carcinoma.
 - Studied the effect of early adulthood obesity as a risk factor for hepatocellular carcinoma. Manuscript published in *Gastroenterology Journal*.
 - Contributed in the Genomic Wide Association Study of HCC in USA.
 - Contributed in the Myriad RBM funding grant that analyzed more than 300 plasma biomarkers in 767 hepatocellular carcinoma patients, 200 healthy controls, and 75 liver cirrhosis patients.
 - ❖ Postdoctoral fellow, Pancreaticobiliary group, 2017-2018
 - ✚ **Mentor: Prof. Milind Javle, MD**
 - Studied the DNA repair genetic aberration in various biliary tract cancers among approximately 500 patients at MD Anderson. The preliminary results was presented as an oral presentation in the 14th International Society of Gastrointestinal Oncology Conference (ISGIO) and as a poster in the Society for Immunotherapy of Cancer annual meeting and in the MD Anderson Annual Postdoctoral Science Symposium and I will be presenting part of the study results in the 2018 Gastrointestinal Symposium of the American Society of Clinical Oncology.
 - Explored the correlation between genomic and immunogenic profiling of 100 intrahepatic cholangiocarcinoma (IHCCA) surgically resected patients to identify the potential candidates for

immunotherapy. The preliminary results presented in the 107th annual United States and Canadian Academy of Pathology conference (USCAP) and the 2018 annual American Society of Clinical Oncology conference.

- Exploring variation in the somatic genomic profiling and immune biomarkers expression in IHCCA among population from different geographic regions. Currently, I am collaborating with the origimed Inc. Genetic company to compare the differences in genomic and immunogenic profiling between IHCCA patients treated at MD Anderson and Chinese patients
- Exploring variation in the somatic genomic profiling and immune biomarkers expression in extrahepatic cholangiocarcinoma among population from different geographic regions. Currently, I am collaborating with the cholangiocarcinoma experts from King Chualongkorn Memorial Hospital, Chualongkorn University, Thailand and Pusan National University Hospital, School of Medicine, Korea, where I will study the somatic genomic profiling and immune biomarkers expression in patients with extrahepatic cholangiocarcinoma treated at MD Anderson in comparison with the Asian patients who have different disease risk factors, to identify the correlation between commonly mutated genes. Recently I received the American Society of Clinical Oncology Global Young Investigator Award that is support this project.
- Analyzed the data from Randomized, Phase I / II Study of Gemcitabine plus IGF-IR antagonist (MK-0646) versus Gemcitabine plus Erlotinib with and without MK-0646 for Advanced Pancreatic Adenocarcinoma. Manuscript published in J Hematol Oncol.
- Participated in developing a protocol for a Phase I, Multicenter Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with AG120 or INCB054828 for Advanced Cholangiocarcinoma
- Participated in developing a protocol for a Phase I study of combination immunotherapy with Pembrolizumab and Bruton Tyrosine Kinase Inhibitor (BGB-3111) for advanced, pre-treated familial pancreatic cancer patients
- Participated in developing a protocol for a multicenter, Single Arm, Phase I/II study of First Line Gemcitabine, Cisplatin, and CPI-613 for Advanced Biliary Cancers.
- Participated in developing a protocol for a Phase 2 Study of Liver Transplantation in Locally Advanced Unresectable None Metastatic Intrahepatic Cholangiocarcinoma Treated with Neoadjuvant Systemic Therapy
- Participated in developing a protocol for a Phase II Study of Nivolumab + Anti-TIM3 antibody for Advanced Cholangiocarcinoma
- Participated in developing a protocol for a Single-arm, phase II proof of concept study of IDO-1 inhibitor Epacadostat in combination with Pembrolizumab in advanced pancreatic cancer with chromosomal instability/ homologous recombination repair deficiency (HRD)
- Participated in developing a protocol about Portal vein stenting in oncology patients with portal vein stenosis and pre-hepatic portal hypertension
- Participated in developing a protocol about Molecular Analysis of Gallbladder Cancer: International Collaborative Project Between MD Anderson Cancer Center and Cancer Institutes from India, Chile, and Egypt.
- Participated in writing and preparation of a grant to study the Association Between Somatic Genetic Mutations and Immune Biomarker Expression in Biliary Tract Cancers
- Participated in writing and preparation of a grant to study the Genomic/ Immunological Heterogeneity of Intrahepatic Cholangiocarcinoma: Clinical and Translational Studies by International Cholangiocarcinoma Research Network

LICENSURES/ CREDENTIALS

- Physician, Egyptian Medical Syndicate, Egypt, 3/2006, under No. 169625
- Specialist of Clinical Oncology, Egyptian Medical Syndicate, Egypt, 12/2009, under No 29195
- Consultant of Clinical Oncology, Egyptian Medical Syndicate, Egypt, 12/2016, under No 29197

EXPERIENCE/SERVICE

Academic Appointments

- Assistant lecturer, Department of Clinical Oncology, Faculty of Medicine, Assiut University Hospitals, Assiut University, Egypt, 3/2010-11/2015
- Lecturer, Department of Clinical Oncology, Faculty of Medicine, Assiut University Hospitals, Assiut

University, Egypt, 11/2015-Present

Institutional Committee Activities

1. **Member**, Post-Graduate Study Committee, Quality Assurance Unit, Faculty of Medicine, Assiut University, Egypt, 2012 – 2013
2. **Member**, Post-Graduate Study Committee, Department of Clinical Oncology, Faculty of Medicine, Assiut University, Egypt, 2012 – 2013
3. **Member**, Quality Assurance unit, Assiut University Hospitals Development Team, Assiut University, Egypt, 2012 – 2013

I have been an active member of the aforementioned committees and I have participated in the following activities:

- Updating the Post-Graduate curriculums for the Master and Doctoral Programs
- Creating the Pre-Employment Orientation Program for new residents
- Developing educational activities to help improving the employee performance
- Organizing the monthly Hospital Grand Rounds
- Creating the Institutional Clinical Care Protocols
- Establishing the Patient Information and Student Hospital Service Kiosks

National Committee Activities

1. **Member**, Health Care Reform of Egypt, Egypt, 2012 – present
2. **Member**, Mentor-Student Research Link Program Committee, Egypt, 2012 – present
3. **Leader**, Patient Information Brochures Project, Egypt, 2014 – present

I have been an active member of the aforementioned committees and I have participated in the following activities:

- Creating the first mentorship project for medical students in Egyptian Universities
- Recruiting colleagues and senior faculty members who were willing to volunteer as mentors
- Interviewing all students applying to join the program in-person
- Mentoring 3 medical students who were interested to continue their career in the field of oncology
 - ❖ I succeeded in building a good relation with my mentees and support them through their publications and presentations.
 - ❖ There abstracts were selected to be presented in 2 international conferences and published in F1000 Journal
 - ❖ Two of them were selected to participate in the European School of Oncology-European Society of Medical Oncology (ESO-ESMO course that is offered for medical students)
 - ❖ One of them was selected to participate in the clinical research methodology course that is organized by Children Cancer Hospital Egypt-57357
- Recruit medical students, residents, fellows, and nurses who are interested to volunteer in Patient Information Brochures Project
- Obtaining financial support for the Patient Information Brochures Project
- Developing, and reviewing the patients educational materials

International Committee Activities

1. **Member**, Hepatocellular Carcinoma Epidemiology Consortium (HCCEC), USA, 2014-present

I have been an active member of the aforementioned consortium and I have participated in the following

activities:

- Developing clinical database for HCC and chronic liver diseases including 18 US institutions
- Organizing the annual HCCEC meeting

2. Associate Program Coordinator, International Cholangiocarcinoma Research Network (ICRN), USA, 2017 – present

I have been an active member of the aforementioned research network and I have participated in the following activities:

- Recruiting International Cancer Institutions to join the ICRN and facilitating both current and future collaboration
- Writing translational researches and clinical trial projects working with the ICRN medical scientific working groups, and applying for national and international grant funding to support the program
- Organizing the annual Asian-Pacific Cholangiocarcinoma conference
- Organizing the annual Cholangiocarcinoma Foundation conference

3. Member, American Society of Clinical Oncology Trainee Council committee, USA, 2018 – present

I have been an active member of the aforementioned committee and I have participated in the following activities:

- Reviewing ASCO University course material and content
- Attending annual in-person Trainee Council meeting at ASCO Annual Meeting
- Sharing the trainee perspective on all ASCO programs.
- Promoting oncology as a career for young investigators

4. Member, American Society of Clinical Oncology Publishing Research Group, USA, 2018 – present

5. Member, American Society of Clinical Oncology Daily News Writing/Podcast Sources, USA, 2018 – present

I have been an active member of the aforementioned committees and I have participated in the following activities:

- Suggesting new interested topics for ASCO Daily News Expert Editorials
- Author ASCO Daily News a topic of interest
- Author ASCO Daily News Clinical Corners
- Participate in the ASCO Daily News podcast program.

Consultantships

Consultant of Clinical Oncology, Assiut University Hospitals, Faculty of Medicine, Assiut University, Egypt, Since 2015, License no. 29197

HONORS AND AWARDS

1. EHA travel bursary, 15th Congress of European Hematology Association, 2010.
2. Technology Transfer Grant, European Society for Radiation and Oncology (ESTRO), 2012
3. ESMO travel bursary, ESMO preceptorship on GI neuroendocrine tumor meeting, Singapore, 2012
4. ESMO travel bursary, ESMO preceptorship on GI neuroendocrine tumor meeting, Berlin, 2012
5. Leadership Award from Inaugural course of oncological sciences travel bursary, Memorial Sloan Kettering Cancer Center and American University Of Beirut, 2013
6. Inaugural course of oncological sciences travel bursary, Memorial Sloan Kettering Cancer Center and American University Of Beirut, July, 2013
7. Postdoctoral and Clinical Fellow oral competition Finalist, Trainee Research Day, UT MD Anderson Cancer

Center, USA, 2014

8. Clinical Research Abstract Finalist, Division of Internal Medicine, Research Retreat poster session, UT MD Anderson Cancer Center, USA, 2014
9. Postdoctoral and Clinical Fellow poster competition Finalist, Trainee Research Day, UT MD Anderson Cancer Center, USA, 2015
10. Research Scholarship, Egyptian Ministry of Higher Education, Egypt, 2013-2015
11. Postdoctoral poster competition Finalist, 7th Annual Postdoctoral Science Symposium, UT MD Anderson Cancer Center, USA, 2017
12. Educational Scholarship from the International Society of Gastrointestinal Oncology (ISGIO), USA, 2017
13. The Marion D. Edwards Fellowship Award in Hepatic Oncology, USA, 2017
14. Global Oncology Young Investigator Award from the Conquer Cancer Foundation and American Society of Clinical Oncology, USA, 2018
15. MD Anderson Postdoctoral Travel Award, USA, 2018

GRANTS and PROTOCOLS

Grants and Contracts

Funded

Principal Investigator, Genomic and Immunologic Profiling in Asian versus Western Extrahepatic Cholangiocarcinoma Patients, Conquer Cancer Foundation and American Society of Clinical Oncology, USA, 7/1/2018 - 6/31/2019, \$50,000.

Pending

Co-investigator, Genomic/ Immunological Heterogeneity of Intrahepatic Cholangiocarcinoma: Clinical and Translational Studies by International Cholangiocarcinoma Research Network, Department of Defense.

Completed

Co-Investigator, Genetic Predisposition for Paraneoplastic Rheumatic Syndromes in Solid Tumor, Faculty of Medicine Grant Office, Assiut University, Egypt, 7/1/2013 - 7/1/2015, 40,000 Egyptian Pound

Not Funded

Collaborator, Association Between Somatic Genetic Mutations and Immune Biomarker Expression in Biliary Tract Cancers, SWOG Early Exploration and Development (SEED) Fund, 10/1/2017 – 9/30/2018, \$50,000

Protocols

Funded

Co-Chair, Pilot Study of Genetic Aberrations in DNA repair in patients with pancreatic cancer [PA15-0059]

Co-Chair, Genomic and Immunologic Profiling in Asian versus Western Extrahepatic Cholangiocarcinoma Patients [PA18-0452]

Co-I, Retrospective, Molecular analysis of Cholangiocarcinoma [PA13-0206]

Co-I, Isolation of circulating tumor cells, cell free nucleic acids and extracellular vesicles from Blood of patients with Biliary Tract Cancer [PA15-0320]

Unfunded

Co-I, Radiogenomic of Cholangiocarcinoma: correlation of Imaging Feature with Multi Genes Panel Sequencing. [PA15-1102]

Co-I, Retrospective Chart Review to Create a Prognostic Model in Untreated Advanced Pancreatic Cancer Patients. [DR07-0627]

Co-I, Chemotherapy outcomes for the treatment of intrahepatic cholangiocarcinoma [DR09-0805]

Co-I, Prospective Evaluation of Portal Vein (PV) Stenting in Patients with PV Stenosis and Gastrointestinal Malignancies [PA18-0712]

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Aboul Hosn M, Abdel-Hafiez N, **Abdel-Wahab R**, Al-Ahmadie A, Anter A, Dbouk H, El Farran H, Mohamed ME,

- Rida K, Mukherji D, O'Reilly EM, Garcia-Aguilar J, Abou-Alfa GK. A Giant Rectal Villous Adenoma with a Malicious Intent. *Gastrointestinal Cancer Res*, 2013;6(5-6):144-149
2. **Abdel-Wahab R**, Shehata S, Hassan MM, Xiao L, Lee J, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, and Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. *Oncotarget*, 2015;6(25): 21193
 3. **Abdel-Wahab R**, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee J, Amin HM, and Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. *J of Hepatocellular Carcinoma*, 2015;2:131-142
 4. Hassan MM, **Abdel-Wahab R**, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. *Gastroenterology*, 2015;149(1):119-129
 5. **Abdel-Wahab R**, Essa HH, Eltaher A, Omar NN and Aboziada MA. Selective bladder preserving treatment by radiation therapy concurrent with either paclitaxel and cisplatin or cisplatin alone following a transurethral surgery. *Annals of Cancer Research*, 2016;3:3
 6. Hassan MM, **Abdel-Wahab R**, Li D, Kaseb AO. Reply. *Gastroenterology*, 2015;149(6):p1643-1644
 7. Nabih O, Essa HH, **Abdel-Wahab R**, Nabil N, Yasien DG. Concurrent Chemoradiotherapy with Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer. *Cancer Biology*, 2015;5(4):107-112
 8. Abaza Y, **Abdel-Wahab R**, Sahin IH, Kaseb AO, Wolff RA, Li D, Raghav K, Shalaby AS, Phan AT, Morris J, Hassan MM. Association between Job Types and the Risk of Hepatocellular Carcinoma in the United States. *Journal of Epidemiologic Research*, 2016;3(1)
 9. Kaseb AO, Hassan M, **Abdel-Wahab R***, Lacin S*, Amin H, Wolff RA, Bashyal M, Bradley K, Yao J, Mistry A, Ohtomo T, Feng J. Evaluating clinical and prognostic implications of glypican 3 in hepatocellular carcinoma. *Oncotarget*, 2016;7(43):69916-69926
 10. Takeuchi S, Rohren EM, **Abdel-Wahab R**, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining Prognosis of Patients with Hepatocellular Carcinoma through Incorporation of Metabolic Imaging Biomarkers. *Eur J Nucl Med Mol Imaging*, 2017;44(6):969-978
 11. Alshamsi HO, Jones J, Fahmawi Y, Dahbour I, **Abdel-Wahab R**, Shaw K, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC, somatic gene mutations in arab patients with colorectal cancer: determination of frequency and distribution pattern. *J Gastrointest Oncol* 2016;7(6):882-902
 12. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes K, Xiao L, **Abdel-Wahab R**, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. *Oncotarget and Therapy*, 2016;9:733-780
 13. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, **Abdel-Wahab R**, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium- 90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. *J of Hepatocellular Carcinoma*, 2016;3:1-7
 14. **Abdel-Wahab R***, Alshamsi HO*, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, ChunYS, Krishnan S, Das P, Koay EJ, Yao J, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large Scale Study in the United States. *Oncotarget*, 2017;93(4):233-242
 15. Ali MA, Lacin S, **Abdel-Wahab R**, Uemura M, Hassan M, Rashid A, Duda DG, and Kaseb AO. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Is there a role for the androgen receptor pathway. *OncoTarget and Therapy*, 2017 March; 10:1403-1412
 16. Hassan MM, Botrus G, **Abdel-Wahab R**, Wolff RA, Li D, Twardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Patt YZ, Morris J, and Kaseb AO. Estrogen Reduces Risk and Improves Outcomes of Hepatocellular Carcinoma in American Women. *Clin Gastroenterol Hepatol*, 2017;15(11):1791-1799
 17. Niekamp A, **Abdel-Wahab R**, Kuban J, Odisio B, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapy in Hepatocellular Carcinoma. *J Clin Med*. 2018 Apr 14;7(4)
 18. Jain A, Borad MJ, Kelley RK, Wang Y, **Abdel-Wahab R**, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab TS, Shroff RT, Javle MM. Cholangiocarcinoma with FGFR

- Genetic Aberrations: A Unique Clinical Phenotype. 10.1200/PO.17.00080 JCO Precision Oncology - published online January 17, 2018.
19. Lunsford KE, Javle M, Heyne K, Shroff RT, **Abdel-Wahab R**, Gupta N, Mobley CM, Saharia A, Victor DW, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM. Liver Transplantation for Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma Treated with Neoadjuvant Therapy: Preliminary Experience from the Methodist - MD Anderson Collaborative. *Lancet gastro*, 2018;1253(18)30045-1
 20. **Abdel-Wahab R**, Varadhachary G, Bhosale PR, Wang X, Fogelman D, Shroff RT, Overman M, Wolf RA, Javle MM. Randomized, Phase I/II Study of Gemcitabine plus IGF-IR antagonist (MK-0646) versus Gemcitabine plus Erlotinib with and without MK-0646 for Advanced Pancreatic Adenocarcinoma. *J Hematol Oncol*. 2018; 11: 71.
 21. **Abdel-Wahab R**, Madison R, Ali S, Wang K, Pant S, Vauthey JN, Shroff RT, Javle M. Genomic Profiling reveals High Frequency of DNA Repair Genetic Aberrations in Gallbladder Cancer. **“Submitted”**
 22. **Abdel-Wahab R**, Agarwal RK, Shalaby AS, Li D, Kaseb AO, Hassan MM. Association Between Alpha-1 Antitrypsin Deficiency and Hepatocellular Carcinoma: A pilot Hospital-Based Case-Control Study. **“Submitted”**
 23. **Abdel-Wahab R**, Hassan MM, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Conrad C, Chun YS, Tzeng CW, Rashid A, Link JT, Sen S, George B, Amin HM, Morris JS, and Kaseb AO. Impact of Integrating IGF-1 into MELD Score on Survival Prediction in Hepatocellular Carcinoma patients. **“Submitted”**
 24. Hu D, **Abdel-Wahab R**, Kuban J, Odisio B, Mahvash A, Murthy R, Hassan MM, Kaseb A, Sheth RA. Hepatopulmonary Shunting: Influence on Survival in Patients Undergoing Y90 Radioembolization and Intrahepatic Arterial Chemotherapy Infusion. **“Submitted”**
 25. Kaseb A, Akce M, Vence LM, Blando JM, Herzog CE, **Abdel-Wahab R**, Amin HM, Hassan MM, Wolff RA, Yao JC, Sharma P. Immune Analysis of Fibrolamellar Hepatocellular Carcinoma. **“Submitted”**
 26. Ahmed K, Fuentes D, Lin JS, **Abdel-Wahab R**, Kaseb AO, Hassan M, Szklaruk J, Hazle JD, Qayyum A, Elsayes KM. Volumetric assessment of hepatocellular carcinoma response to treatment using a random forest-based automated segmentation protocol. **“Submitted”**
 27. Kaseb AO, Raghav KP, Akce M, **Abdel-Wahab R**, Girard L, Avritscher R, Murthy R, Chasen B, Elsayes K, Elbanan M, Kappadath SC, Hassan MM, Xiao L, Morris JS, Odisio BC, Ohaji C, Iwasaki M, George B, Amin HM, Wolff RA, Vauthey JN, Yao JC, and Mahvash A. A prospective phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C. **“Submitted”**
 28. Kaseb AO, Sanchez NS, Link JT, Sen S, Kelley RK, Tan B, Bocobo AG, Lim HC, **Abdel-Wahab R**, Uemura M, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Banks KC, Lanman RB, Talasaz AA, Mills-Shaw KR, Wolf RA, Yao JC, Meric-Bernstam F, Ikeda S, and Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. **“Submitted”**
 29. Marcus RK, Lillemoie HA, **Abdel-Wahab R**, Shroff RT, Javle MM, Aloia TA. The impact of tumor genomic profile on the efficacy of adjuvant chemotherapy for resectable intrahepatic cholangiocarcinoma. **“In preparation”**
 30. Kok M.Y., Davis J.S., Al-Assi K., Li D., Hatia R., **Abdel-Wahab R.**, Akce M., Uemura M., Kaseb A., Chang S., Hassan M.M. Factors Associated with Longer Survival of Patients with Advanced Hepatocellular Carcinoma - A Single Institution Experience. **“In preparation”**
 31. Pestana RC, Hassan M, **Abdel-Wahab R**, Abugabal YI, Kaseb AO. Clinical and prognostic significance of serum levels of angiopoietin-1 (sAng-1) and angiopoietin-2 (sAng-2) in hepatocellular carcinoma (HCC). **“In preparation”**

Other Articles

1. Image Guided Gynecological Brachytherapy, **Abdel-Wahab R**. ESTRO Newsletter, 2013; May- June: 88: 55-56. https://www.estro.org/binaries/content/assets/estro/about/newsletter/estro-newsletter-may-june_printer-friendly.pdf
2. Exploring Optimal Timing for MSI, MMR, PD-L1 Testing, Abdel-Wahab R. 2018 Gastrointestinal Cancers Symposium Daily News, 2018, January 11. <https://gicasym.org/daily-news/exploring-optimal-timing-msi-mmr-pd-l1-testing>

Abstracts

1. **Abdel-Wahab R**, Eltaher AM, Essa HH, Eid SSM. Effective and less toxic Trimodality Approach in muscle Invasive Urinary Bladder Cancer. *J Clin Oncol* 31, 2013: e15505

2. Ahmed O and **Abdel-Wahab R**. Solitary Skeletal Muscle Metastasis from Primary Colon Cancer: A Case Report and Review of Literature. United Arab Emerita Cancer Congress, 2013
3. Ahmed O and **Abdel-Wahab R**. Solitary Skeletal Muscle Metastasis from Primary Colon Cancer: A Case Report and Review of Literature. F1000 Poster, Published 14 Nov 2013
4. Ahmed K, Abou-Taleb H, **Abdel-Wahab R**. Induction Cancer for Cancer – Part 1: The Role of HMP Shunt in Cancer Metabolism. F1000 Poster, Published 9 Oct 2013
5. **Abdel-Wahab R**, Hassabo HM, Elantably A, Raghav KPS, Kaseb AO, Herlong F, KC Young, Botrus G, Shalaby A, Hassan M. Prognostic Effect of Statins on Hepatocellular Carcinoma in Presence and Absence of Metformin intake. *Hepatology* 60, 2014 (suppl; abstr 1317)
6. **Abdel-Wahab R**, Hassan M, Shehata S, Essa HH, Kaseb AO. The differential clinicopathologic features and survival outcome between hepatitis C–related HCC patients in the United States versus Egypt. *J Clin Oncol* 32, 2014: e15128
7. **Abdel-Wahab R**, Shehata S, Hassan M, Xiao L, Lee J, Cheung S, Hassabo HM, Shalaby AS, Essa HH, Mossad E, Raghav K, Rashid A, Wolff RA, Morris J, Amin HM, Kaseb AO. International validation of an IGF-CTP scoring system for assessing hepatic reserve in hepatocellular carcinoma. *J Clin Oncol* 33, 2015: e15140
8. **Abdel-Wahab R**, Hassan M, Raghav K, Shalaby AS, Botrus G, Xiao L, Morris J, Wolff RA, Kaseb AO. Single institutional experience of bevacizumab-based regimens in treatment of hepatocellular carcinoma. *J Clin Oncol* 33, 2015: e15138
9. Al-Shamsi HO, **Abdel-Wahab R**, Hassan M, Botrus G, Shalaby AS, Wolff RA, Kaseb AO. Natural History of T1N0M0 Hepatocellular carcinoma: Large scale study in the United States. *J Clin Oncol* 33, 2015: e15120
10. Uemura MI, Kaseb AO, **Abdel-Wahab R**, Raghav K, Botrus G, Hawk E, Wolff RA, Morris J, Hassan M. Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S. cancer center: Do clinicopathologic features or patient outcomes differ by the potentially causative viruses?. *J Clin Oncol* 33, 2015: 4011
11. Botrus G, Shalaby AS, Kaseb AS, Lenzi R, **Abdel-Wahab R**, Wolff RA, Hassan M. The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. *J Clin Oncol* 33, 2015: 4019
12. Kaseb AO, Al-Shamsi HO, Morris J, Iwasaki M, Xiao L, **Abdel-Wahab R**, Raghav K, Hassan M, Hassabo HM, Wolff RA. Phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma. *J Clin Oncol* 33, 2015: 4088
13. **Abdel-Wahab R**, Essa HH, Eltaher A, Aboziada MA, Shehata S. Concurrent chemoradiotherapy with paclitaxel and cisplatin in muscle-invasive bladder cancer. *Annals of Oncology*, 2016;27(6): 266-295
14. Hassan MM, **Abdel-Wahab R**, Kaseb AO, Shalaby A, Botrus G, Lacin S, Morris JS, Amin HM, Wolff RA, Hwang JP, Li D, Torres HA, Shalaby A, Lenzi R, Yao JC, Joss JA, Jalal PK, Khaderi S, Ballard K, Hawk E. Hepatocellular Carcinoma Screening in High-Risk Populations in the United States. *AASLD*, 2014; 61362 (Suppl; abstr 1317)
15. Hassan M, **Abdel-Wahab R**, Wolff RA, Botrus G, Shalaby A, Li D, Torres HA, Morris JS, Ballard K, Hawk E, Shalaby A, Amin HM, Yao JC, Lenzi R, Joss JA, Jalal PK, Khaderi S, Lacin S, Kaseb AO. Growth Hormone and Hepatocellular Carcinoma. *AASLD*, 2016;144147 (Suppl; abstr 1253)
16. **Abdel-Wahab R**, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Impact of Integrating Insulin like growth factor-1 (IGF-1) in Model for end stage liver disease (MELD) scores on Predicting Hepatocellular Carcinoma Patients' Survival. *J Clin Oncol* 34, 2016 (suppl; abstr 4080)
17. **Abdel-Wahab R**, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Integrating Insulin like growth factor-1 (IGF-1) score into Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) Scores. *J Clin Oncol* 34, 2016 (suppl; abstr 4081)
18. Lacin S, **Abdel-Wahab R**, Hassan M, Shalaby AS, Amin HM, Wolff RA, Yao JC, Mistry A, Feng JD, Ohtomo

- T, Kaseb AO. Evaluating Clinical and Prognostic Implications of Glypican 3 in Hepatocellular Carcinoma. *J Clin Oncol* 34, 2016 (suppl; abstr e15619)
19. Lacin S, **Abdel-Wahab R**, Elbanan M, Abdelbaki S, Shalaby AS, Hassan M, Wei W, Sun J, Elsayes KM, Kaseb AO. Impact of Sorafenib Treatment on Portal Hypertension in Hepatocellular Carcinoma Patients. *J Clin Oncol* 34, 2016 (suppl; abstr e15637)
 20. Shalaby AS, Botrus G, Kaseb AO, Li D, **Abdel-Wahab R**, Wolff RA, Lacin S, Javle MM, Hawk E, Hassan M. The Protective Effect of physical activity on Risk of Hepatocellular Carcinoma in USA. *J Clin Oncol* 34, 2016 (suppl; abstr e15642)
 21. Jain A, Shroff RT, Kelley RK, Kaseb AO, Wang Y, **Abdel-Wahab R**, Ahn DH, Bocobo AG, Meric-Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. *J Clin Oncol* 34, 2016 (suppl; abstr 109)
 22. Al-Shamsi HO, **Abdel-Wahab R**, Hassan M, Botrus G, Shalaby AS, Wolff RA, Kaseb AO. Natural History of T1N0M0 Hepatocellular carcinoma: Large scale study in the United States. *J Clin Oncol* 34, 2016 (suppl 4S; abstr 416)
 23. **Reham Abdel-Wahab**, Hassan M, Lacin S, Shalaby AS, Afshar-Kharghan V, Kaseb AO. Erythropoietin And Hepatocellular Carcinoma: What is Patients Survival Outcome?. *J Clin Oncol* 35, 2017 (suppl; abstr e15660)
 24. **Abdel-Wahab R**, Hassan MM, Wolff RA, Lacin S, Al-Shamsi H, Raghav KPS, Shalaby AS, Yao JC, Kaseb AO. Association of Elevated Alpha-1 Antitrypsin with Advanced Clinicopathological Features of Hepatocellular Carcinoma. *J Clin Oncol* 35, 2017 (suppl 4S; abstract 289)
 25. Kaseb AO, **Abdel-Wahab R**, Hassan M, Xiao L, Raghav KPS, Girard L, Amin HM, Morris J, Yao JC. A prospective biomarker study to assess IGF-1 score ability to sub-stratify Child-Turcotte-Pugh classes and predict response to systemic therapy in Hepatocellular Carcinoma. *J Clin Oncol* 35, 2017 (suppl; abstr e15662)
 26. Kaseb AO, **Abdel-Wahab R**, Murthy R, Hassan M, Raghav KSP, Xiao L, Morris J, Avritscher R, Odisio BC, Ohaji C, Wolff RA, Yao JC, Mahvash A. A Phase II Study of Sorafenib and Yttrium-90 glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C. *J Clin Oncol* 35, 2017 (suppl; abstr 4083)
 27. Kaseb AO, **Abdel-Wahab R**, Murthy R, Hassan M, Raghav KSP, Xiao L, Morris J, Avritscher R, Odisio BC, Ohaji C, Wolff RA, Yao JC, Mahvash A. A Phase II Study of Sorafenib and Yttrium-90 glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C. *Annals of Oncology* (2017) 28 (suppl_5): v209-v268.
 28. Jain A, **Abdel-Wahab R**, Shroff RT, Zuo M, Weatherly J, Meric-Bernstam F, Isaacs R, Ali SM, Bekaii-Saab TS, Javle MM. Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC). *J Clin Oncol* 35, 2017 (suppl; abstr 4086)
 29. Khalaf AM, Fuentes DT, Ahmed K, **Abdel-Wahab R**, Hassan M, Kaseb AO, Hazle JD, Elsayes KM. Quantitative CT Imaging Features for Hepatocellular Carcinoma (HCC) with b-catenin (CTNNB1) gene mutation. *J Clin Oncol* 35, 2017 (suppl 4S; abstract 253)
 30. Shalaby A, Javle MM, Shroff RT, Abousamra AOS, **Abdel-Wahab R**, Rallapalli V, Li D, Hassan M. Early Obesity and Risk of Cholangiocarcinoma in the United states. *J Clin Oncol* 35, 2017 (suppl 4S; abstract 239)
 31. **Abdel-Wahab R**, Shroff R, Vauthey JN, Koay EJ, Ali S, Kwong L, Zuo M, Rashid A, Javle M. DNA Repair Genetic Aberrations and Tumor Mutation Burden in Biliary Tract Cancers. *Society of Immunotherapy of Cancer*, 2017 "Accepted"
 32. Kok M, Davis JS, Al-Assi K, Li D, Hatia R, **Abdel-Wahab R**, Akce M, Uemura M, Kaseb A, Chang S, Hassan M. Clinical factors affect long-term survival of advanced hepatocellular carcinoma patients. *Cancer Prevention and Research Institute of Texas*, 2017 "Accepted"
 33. Goyal L, Kelley RK, Kiedrowski L, Catenacci D, Mody K, Shroff R, Parikh A, Reyes S, Maurer JR, Grace A, **Abdel-Wahab R**, Corcoran RB, Fanta P, Cusnir M, Nagy B, Lanman R, Morse M, Tan B, Javle M, Zhu AX.

- Blood-based genomic profiling of cell-free circulating tumor DNA (ctDNA) in patients with biliary tract cancer (BTC). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, 2017 "Accepted"
34. **Abdel-Wahab R**, Ali SM, Borad MJ, Shroff RT, Kwong L, Vauthey JN, Koay EJ, Zuo M, Rashid A, Schrock AB, Ross JS, Bekaii-Saab TS, Javle MM. Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 263).
 35. Marcus RK, Lillemoe HA, **Abdel-Wahab R**, Shroff RT, Javle MM, Aloia TA. The impact of tumor genomic profile on the effectiveness of adjuvant chemotherapy in resectable intrahepatic cholangiocarcinoma. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 474).
 36. Kaseb AO, Zohner E, Xiao L, Wang Z, Hassan M, **Abdel-Wahab R**, Ballard K, Wolff RA, Amin HM, Wang W, Yao JC, Morris J. Global Protein Aberration Score (GloPAS): A comprehensive risk score to predict hepatocellular carcinoma biology and estimate patients' survival. *J Clin Oncol* 36, 2018 (suppl 4S; abstr 287).
 37. Solis LM, Foo WC, Parra ER, Mino B, **Abdel-Wahab R**, Wistuba I, Kwong L, Javle M, Shroff R. Tumor-Associated Inflammatory Cells And Immune-Checkpoints markers Correlates With Clinicopathological Characteristics In Intrahepatic Cholangiocarcinoma (ICC). USCAP conference, 2018.
 38. **Abdel-Wahab R**, Kelley RK, Kiedrowski LA, Catenacci D, Mody K, Shroff RT, Parikh A, Reyes S, Maurer JR, Corcoran RB, Fanta P, Cusnir M, Nagy RJ, Lanman RB, Morse M, Tan B, Zhu A, Javle MM, Goyal L. Blood-based Genomic Profiling of Cell-free DNA (cfDNA) in Biliary Tract Cancer Patients. Cholangiocarcinoma Foundation annual conference, 2018.
 39. Carmagnani Pestana R., Solis L, Wang X, **Abdel-Wahab R**, Chen H, Foo WC, Kwong L, Javle MM, Wistuba II, Shroff RT. Immunoprofiling in Intrahepatic Cholangiocarcinoma (IHCC). *J Clin Oncol* 36, 2018 (suppl; abstr 12049)
 40. **Abdel-Wahab R**, Liu S, Ross JS, Schrock AB, Ali SM, Cao J, Zhuang L, Lin J, Shroff RT, Javle MM, Wang K, Zhao H. Genomic diversity between Asian and United States intrahepatic cholangiocarcinoma patients. *J Clin Oncol* 36, 2018 (suppl; abstr e16137)
 41. Abugabal YI, Hassan M, **Abdel-Wahab R**, Lacin S, Pestana RC, Wolff RA, Yao JC, Kaseb AO. Utility of Neupilin-1 in predicting survival in patients with hepatocellular carcinoma. *J Clin Oncol* 36, 2018 (suppl; abstr e16142)
 42. Kaseb AO, Abugabal YI, **Abdel-Wahab R**, Lacin S, Botrus G, Pestana RC, Wolff RA, Yao JC, Hassan M. Prognostic significance of periostin in patients with hepatocellular carcinoma. *J Clin Oncol* 36, 2018 (suppl; abstr e16143)
 43. Pestana RC, Hassan M, **Abdel-Wahab R**, Abugabal YI, Kaseb AO. Clinical and prognostic significance of serum levels of angiopoietin-1 (sAng-1) and angiopoietin-2 (sAng-2) in hepatocellular carcinoma (HCC). *J Clin Oncol* 36, 2018 (suppl; abstr e16152)
 44. Low JM, Abdelsalam ME, Odisio BC, Figueira TA, **Abdel-Wahab R**, Hassan M, Kaseb AO. Oncologic effectiveness of transarterial chemoembolization in local control of large hepatocellular carcinoma. *J Clin Oncol* 36, 2018 (suppl; abstr e16148)
 45. Abdelhakeem AAA, Rallapalli V, **Abdel-Wahab R**, Javle M, Hassan MM. Risk Factors of Intrahepatic Cholangiocarcinoma in Absence of Viral Hepatitis and Primary Sclerosing. "Accepted for poster presentation in AASLD 2018"
 46. Pestana RC, Hassan M, **Abdel-Wahab R**, Abugabal YI, Kaseb AO. Clinical and prognostic significance of serum levels of angiopoietin-1 (sAng-1) and angiopoietin-2 (sAng-2) in hepatocellular carcinoma (HCC). "Accepted for poster presentation in AASLD 2018"
 47. Pestana RC, Hassan M, **Abdel-Wahab R**, Abugabal YI, Girard L, Hatia R, Nguyen V, Overman M, Morris J, Rashid A, Wolff RA, Amin HM, Kaseb AO. Plasma GH as a diagnostic and prognostic biomarker in HCC without

cirrhosis. "Submitted for the 2019 GI ASCO Conference"

48. Abdelhakeem A, Kaseb AO, Hatia R, **Abdel-Wahab R**, Amin HM, Hassan M. Distribution of Insulin Growth Factor-1 (IGF-1) Binding Protein in Hepatocellular Carcinoma with and without Cirrhosis. "Submitted for the 2019 GI ASCO Conference"
49. Abugabal YI, Hassan M, Xiao L, Morris J, Pestana RC, **Abdel-Wahab R**, Hatia R, Chang P, Girard L, Rashid A, Bhawana G, Overman M, Abdelhakeem A, Wolff RA, Amin HM, Kaseb AO. IGF-Child-Pugh Score as a Predictor of Treatment Outcome in Child-Pugh A, Advanced Hepatocellular Carcinoma Patients Undergoing Sorafenib Therapy. "Submitted for the 2019 GI ASCO Conference"

Book Chapters

1. Lacin S, Rashid A, Chun YS, Odisio C, Koay EJ, **Abdel-Wahab R**, Kaseb AO. Hepatocellular Carcinoma. "In preparation"
2. Mizrahi J, **Abdel-wahab R**, Javle M. Clinical Trials and Novel / Emerging Treatment for Intrahepatic Cholangiocarcinoma. "In preparation"

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

- Gastrointestinal Malignancy – a specific issue from the International Journal of Gastroenterology Disorders & Therapy

Member of Editorial Review Board

- Journals of Oncology Research and Therapy
- Current Trends in Radiation Oncology and Cancer
- ECronicon Cancer Open Access Journal
- International Journal of Clinical Oncology and Cancer Research

Journal Reviewer

- BMC Cancer
- Cancer Management and Research
- Cancer Science & Research: Open Access
- Clinical Epidemiology
- Clinical Interventions in Aging
- Clinical Medicine Insights: Gastroenterology
- Clinical Medicine Insights: Oncology
- Egyptian Journal of Radiology and Nuclear Medicine
- Gastrointestinal Cancer: Target and Therapy
- JCO Clinical Cancer Informatics
- Journal of Cancer Therapy
- Oncotarget
- OncoTarget and Therapy
- Patient Preference and Adherence
- Supportive care in cancer

Other Editorial and Review Activities

American Society of Clinical Oncology (ASCO) annual educational book

TEACHING

Formal Teaching

As an Assistant lecturer, Department of Clinical Oncology, Faculty of Medicine, Assiut University Hospitals, Assiut University, Egypt, I participate in the Oncology Journal Club, Assiut University Hospital, Faculty of Medicine, Assiut, Egypt:

- Value of Stereotactic Radiotherapy in Management of Deeply Seated Tumors
- Inflammatory Breast Cancer
- Metastasis of Unknown Primary

- Management of Mesothelioma
- Paraneoplastic Manifestations and Lymphoma
- Management of Elderly Patients with Cancer
- Management of Prostatic Carcinoma
- Best Management of Hepatic Metastasis
- Choosing the Best Management Approaches for Epithelial Ovarian Cancer patients
- Controversies in Management of Desmoid Tumors
- Current Treatment of Chronic Myeloid Leukemia

Supervisory Teaching

Direct Supervision

Medical Students

Kareem Ahmed, Assiut University Faculty of Medicine, Egypt, 2012-2013

Omnia Omar, Assiut University Faculty of Medicine, Egypt, 2012-2013

Mohamed Abdallah, Al-Azhar University Faculty of Medicine, Egypt, 2012-2013

Postdoctoral Research Fellows

Sahin Lacin, MD, GI Medical Oncology Department, MD Anderson Cancer Center, USA, 2015-2016

Clinical Residents and Fellows

Marc Uemura, MD, GI Medical Oncology Department, MD Anderson Cancer Center, USA, 2015 - 2017

Mehmet Akce, MD, GI Medical Oncology Department, MD Anderson Cancer Center, USA, 2016 - 2017

Graduate Students [This can go up after Medical Students]

Ahmed Shalaby, MD, GI Medical Oncology Department, MD Anderson Cancer Center, USA, 2013 -2017

Aneeqa Dar, MD, GI Medical Oncology Department, MD Anderson Cancer Center, USA, 2014 – 2015

Ahmed Abousamra, GI Medical Oncology Department, MD Anderson Cancer Center, USA, MD, 2016 - 2017

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

- 2nd Upper Egypt Conference of Respiratory Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt, Organizing Committee Member, 2003
- 2nd Clinical Oncology Department Conference (Towards Individualized Therapies in Cancer Management in Egypt), Luxor, Egypt, Organizing and scientific Committee Member, 2010
- 3rd Clinical Oncology Department Conference (Recent Update in Cancer Management), Luxor, Egypt, Organizing and scientific Committee Member, 2012
- The 29th Faculty of Medicine Annual Conference (Faculty of Medicine from Academic Accreditation towards Hospital Accreditation: Challenges & Opportunities), Faculty of Medicine, Assiut University, Assiut, Egypt, Organizing Committee Member, 2012
- Pre-Employment Orientation Program for New Resident Doctors, Assiut University Hospitals, Egypt, Planning Committee Member, 2013
- World Congress on Oncology and Immuno Oncology, Amsterdam, Netherland, Organizing Committee Member, 2018
- 2nd annual Hepatocellular Carcinoma Epidemiology Consortium meeting, Organizing Committee Member, 2017
- 2nd Asia-Pacific Cholangiocarcinoma Conference, Thailand, Organizing Committee Member, 2018
- 5th Cholangiocarcinoma Foundation Annual Conference, Salt Lake, USA, Organizing Committee Member, 2018

Presentations at National or International Conferences

Invited

1. 1st annual world congress of digestive disease (WCDD-2015), Nanjing, China, 2015.
2. 14th Annual Congress of International Drug Discovery Science and Technology, South Korea, 2016
3. 14th Annual International Gastrointestinal Oncology Conference, Arlington, USA, 2017

Other, Including Scientific Exhibitions

1. **Abdel-Wahab R.** Integrative Medicine and Lung Cancer. 1st Annual Integrated Medicine Conference, Assiut, Egypt, 2012.
2. **Abdel-Wahab R.** Challenges in Treatment of Anemia with Cancer. 3rd Annual Assiut University Oncology Conference, Egypt, 2012.
3. **Abdel-Wahab R.** Natural History of HCC in African American. 2nd Hepatocellular Carcinoma Epidemiology Consortium (HCCEC), Houston, USA, 2014.
4. **Abdel-Wahab R,** Hassan M, Shehata S, Essa HH, Kaseb AO. The Difference between HCV- Related HCC Patients in USA versus Egypt. Trainee Research Day, MD Anderson Cancer Center, Houston, USA, 2014
5. Jain A, Shroff RT, Kelley RK, Kaseb AO, Wang Y, **Abdel-Wahab R,** Ahn DH, Bocobo AG, Meric- Bernstam F, Isaacs R, Bekaii-Saab TS, Javle MM. FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy. Annual ASCO Meeting, Chicago, USA, 2016.
6. **Abdel-Wahab R,** Ali S, Shroff R, Vauthey JN, Koay EJ, Kwong L, Zuo M, Rashid A, Javle M. DNA Repair Gene Somatic aberrations and Tumor Mutation Burden in Cholangiocarcinoma. 14th International Society of Gastrointestinal Oncology, Arlington, USA, 2017
7. Hu D, **Abdel-Wahab R,** Kuban J, Odisio B, Mahvash A, Hassan M, Kaseb A, Sheth R. High hepatopulmonary shunting improves survival in patients undergoing intrahepatic arterial chemotherapy infusion for treatment of liver metastases. Annual SIR meeting, Washington, USA, 2017
8. Niekamp A, **Abel-Wahab R,** Kuban J, Odisio B, Mahvash A, Hassan M, Kaseb A, Sheth R. Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma. Annual SIR meeting, Washington, USA, 2017

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

- European Society of therapeutic Radiation Oncology (ESTRO), Member, 2009-present
- Egyptian Cancer Society (ECS), Member, 2010-present
- European Society of Medical Oncology (ESMO), Member, 2012-2013
- European Association for Cancer Research (EACR), Member, 2012-2013
- American Society of Clinical Oncology (ASCO), Member, 2012-present
- American Collage of Radiation Oncology (ACRO), Member, 2012-present
- American Society of Therapeutic Radiology and Oncology (ASTRO), Member, 2013-present Hepatocellular Carcinoma Epidemiology Consortium (HCCEC), Member, 2014-present
- Society of Immunotherapy of Cancer (SITC), Member, 2017
- International Cholangiocarcinoma Research Network, Member and Program Research Coordinator, 2017-present

UNIQUE ACTIVITIES

Leadership

1. Faculty and Leadership Development Center, Assiut University, Assiut, Egypt, 2008-2010.
 - Communication Skills
 - International Publishing of Research Use of Technology in Teaching
 - Legal and Financial Aspects in University Environment Research Ethics
 - Credit Hour System
 - Quality Standards in Teaching
 - E-Learning

- Time and Conference Management Effective Presentation
- Conference Organization

Research

1. Writing and Publishing Scientific Articles Workshop, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014
2. Writing Retreat, The University of Texas MD Anderson Cancer Center, Houston, , TX, 2014
3. National Institution of Health training (FY13-14 Responsible Conduct of Research), MD Anderson cancer Center, Houston, TX, 10/2014-1/2016
 - Data acquisition, management, sharing and ownership
 - Ethical issues in biomedical research
 - Peer review
 - Research misconduct and policies for handling misconduct
 - Safe laboratory practice
 - Conflict of interest and commitment
 - Publication practices and responsible authorship
 - Mentor/Trainee responsibility
4. Clinical Research Curriculum, The University of Texas School of Medicine, Houston, TX, 4/2015- 2/2016
 - Translational research Literature appraisal
 - Clinical trials
 - NIH grant submission and review pathway
 - Introduction to epidemiology
5. CERTaIN Pragmatic Clinical Trials: A Hands On Workshop, The University of Texas MD Anderson Cancer center, Houston, Texas, 2017

Education

1. Mentor students through the Publons Academy Practical Peer Review Training Course
2. Health outreach event (Breast Cancer is a Real Health Problem in Egypt: How can we early detect it?), Faculty of Medicine, Assiut University & the National Council for Women in Egypt, Assiut, Egypt, 2013
3. Public Health Campaign, Faculty of Medicine, Assiut University & the National Council for Women in Egypt, Assiut, Egypt, 2013

References available upon request